|
Camostat mesylate
|
TMPRSS2 suppressor, the effect on S proteins
|
Treatment of chronic pancreatitis, postoperative reflux esophagitis, and SARS-CoV
|
[5, 92]
|
|
Olumiant (Baricitinib)
|
JAK suppressor, the effect on S proteins
|
Treatment of rheumatoid arthritis
|
[93]
|
|
rhACE2 (APN01)
|
Decrease in proteolytic binding peptide angiotensin II
|
SARS-CoV infections, cardiovascular disease
|
[5, 94]
|
|
Umifenovir (Arbidol/ARB)
|
Preventing HA protein-interceded membrane fusion
|
influenza infection
|
[95]
|
|
T-705 (Favipiravir)
|
Inhibiting RdRp
|
influenza viruses, WNV, yellow fever virus, FMDV
|
[96, 97]
|
|
Abacavir (Ziagen)
|
RTIs (reverse-transcriptase inhibitors)
|
Treatment of HIV
|
[98]
|
|
Roflumilast (Daxas/Daliresp)
|
Preventing PDE4
|
COPD
|
[98]
|
|
Almitrine mesylate
|
is a respiratory stimulant
|
COPD
|
[98]
|
|
Chloroquine phosphate
|
IFN-α pathway
|
antimalarial
|
[99, 100]
|
|
Remdesivir
|
RdRp inhibitor
|
Treatment of Ebola and Marburg infections
|
[101]
|
|
Convalescent plasma
|
viral-specific antibodies
|
Ebola virus, H1N1, SARS-CoV-1, MERS-CoV
|
[102]
|
